Hoang, Stephen A.
Oseini, Abdul
Feaver, Ryan E.
Cole, Banumathi K.
Asgharpour, Amon
Vincent, Robert
Siddiqui, Mohammad http://orcid.org/0000-0001-7392-7489
Lawson, Mark J.
Day, Nathan C. http://orcid.org/0000-0002-6714-8611
Taylor, Justin M. http://orcid.org/0000-0003-4590-0777
Wamhoff, Brian R.
Mirshahi, Faridoddin
Contos, Melissa J.
Idowu, Michael
Sanyal, Arun J.
Article History
Received: 11 December 2018
Accepted: 29 July 2019
First Online: 29 August 2019
Competing Interests
: Arun Sanyal: Dr. Sanyal is President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect. He has served as a consultant to Hemoshear, Echosens, AbbVie, Astra Zeneca, Nitto Denko, Ardelyx, Conatus, Nimbus, Amarin, Salix, Tobira, Takeda, Novo Nordisk, Fibrogen, Jannsen, Gilead, Boehringer, Lilly, Zafgen, Novartis, Pfizer, Immuron, Exhalenz and Genfit. He has been an unpaid consultant to Intercept, Immuron, Galectin, Fractyl, Syntlogic, Affimune, Chemomab, Nordic Bioscience and Bristol Myers Squibb. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Echosens, Intercept, Merck, Astra Zeneca, Malinckrodt, Cumberland and Novartis. He receives royalties from Elsevier and UptoDate. Stephen Hoang, Ryan Feaver, Banumathi Cole, Mark Lawson, Nathan Day, Justin Taylor, and Brian Wamhoff are Employees of HemoShear Therapeutics.